Mutational status of EGFR, BRAF, PI3KCA and JAK2 genes in endocrine tumors

International Journal of Cancer

Volumn 124, Issue 3, 2009, Pages 751-753

  Ameur, Nabahet ^a   Lacroix, Ludovic ^b   Motte, Nelly ^b   Baudin, Eric ^b   Caillou, Bernard ^b   Ducreux, Michel ^b   Elias, Dominique ^b   Chanson, Philippe ^c   Schlumberger, Martin ^b   Bidart, Jean Michel ^a,b  

^a CNRS   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; JANUS KINASE 2; BRAF PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PI3KCA PROTEIN, HUMAN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; ENDOCRINE TUMOR; GENE MUTATION; GENE SEQUENCE; HUMAN; LETTER; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; THYROID CARCINOMA; ADULT; GENETICS; MALE; MIDDLE AGED; NUCLEOTIDE SEQUENCE;

ADULT; DNA MUTATIONAL ANALYSIS; ENDOCRINE GLAND NEOPLASMS; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTION FACTORS;

EID: 58149316643     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23999     Document Type: Letter

References (31)

1. DeLellis RA, Llyod RV, Heitz PU, Eng C, eds. Tumours of endocrine organs. World Health Organization Classification of Tumours. Lyon: Pathology & Genetics IARC Press, 2004. 320.
2. Leotlela PD, Jauch A, Holtgreve-Grez H, Thakker RV. Genetics of neuroendocrine and carcinoid tumours. Endocr Relat Cancer 2003;10:437-50.
3. Zikusoka MN, Kidd M, Eick G, Latich I, Modlin IM. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer 2005;104:2292-309.
4. Oberg K. Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment. Curr Opin Oncol 2005;17:386-91.
5. Weber F, Eng C. Update on the molecular diagnosis of endocrine tumors: toward-omics-based personalized healthcare? J Clin Endocr Metab 2008;93:1097-104.
6. Syder AJ, Karam SM, Mills JC, Ippolito JE, Ansari HR, Farook V, Gordon JI. A transgenic mouse model of metastatic carcinoma involving transdifferentiation of a gastric epithelial lineage progenitor to a neuroendocrine phenotype. Proc Natl Acad Sci USA 2004;101:4471-6.
7. De Herder WW, Hofland LJ, van der Lely AJ, Lamberts SW. Somatostatin receptors in gastro-entero-pancreatic neuroendocrine tumours. Endocr Relat Cancer 2003;10:451-8.
8. Baudin E. Gastroenteropancreatic endocrine tumors: clinical characterization before therapy. Nat Clin Pract Endocrinol Metab 2007;3:228-39.
9. Yao JC, Hoff PM. Molecular targeted therapy for neuroendocrine tumors. Hematol Oncol Clin North Am 2007;21:575-81.
10. De Groot JW, Links TP, Plukker JT, Lips CJ, Hofstra RM. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 2006;27:535-60.
11. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004;6:313-19.
12. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of nonsmall cell lung cancer. Clin Cancer Res 2006;12:4441s-4445s.
13. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
14. Satrapie L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 2008;93:278-84.
15. James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med 2005;11:546-54.
16. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399-404.
17. Motté N, Saulnier P, Le Couedic JP, Soria JC, Delaloge S, Boige V, Pautier P, Vainchenker W, Bidart JM, Villeval JL. Mutations in JAK2V617F homologous domain of JAK genes are uncommon in solid tumors. Int J Cancer 2007;121:2113-15.
18. Lacroix L, Pautier P, Duvillard P, Motté N, Saulnier P, Bidart JM, Soria JC. Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations. Int J Cancer 2006;118:1068-9.
19. Ewing I, Pedder-Smith S, Franchi G, Ruscica M, Emery M, Vax V, Garcia E, Czirják S, Hanzély Z, Kola B, Korbonits M, Grossman AB. A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin Endocrinol (Oxf) 2007;66:348-52.
20. Perren A, Schmid S, Locher T, Saremaslani P, Bonvin C, Heitz PU, Komminoth P. BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors. Endocr Relat Cancer 2004;11:855-60.
21. Tannapfel A, Vomschloss S, Karhoff D, Markwarth A, Hengge UR, Wittekind C, Arnold R, Horsch D. BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumors. Am J Clin Pathol 2005;123:256-60.
22. Wang GG, Yao JC, Worah S, White JA, Luna R, Wu TT, Hamilton SR, Rashid A. Comparison of genetic alterations in neuroendocrine tumors: frequent loss of chromosome 18 in ileal carcinoid tumors. Mod Pathol 2005;18:1079-87.
23. Papouchado B, Erickson LA, Rohlinger AL, Hobday TJ, Erlichman C, Ames MM, Lloyd RV. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol 2005;18:1329-35.
24. Gilbert JA, Lloyd RV, Ames MM. Lack of mutations in EGFR in gastroenteropancreatic neuroendocrine tumors. N Engl J Med 2005; 353:209-10.
25. Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN, Holsinger FC, Sherman SI et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 2004;10:8594-602.
26. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A, Cameselle-Teijeiro J, Santoro M. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 2005;65:10199-207.
27. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, Vasko V, Xing M. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 2007;13:1161-70.
28. Van Nederveen FH, Perren A, Dannenberg H, Petri BJ, Dinjens WN, Komminoth P, de Krijger RR. PTEN gene loss, but not mutation, in benign and malignant phaeochromocytomas. J Pathol 2006;209:274-80.
29. Kedzia C, Lacroix L, Ameur N, Ragot T, Kelly PA, Caillou B, Binart N. Medullary thyroid carcinoma arises in the absence of prolactin signaling. Cancer Res 2005;65:8497-503.
30. Costa P, Catarino AL, Silva F, Sobrinho LG, Bugalho MJ. Expression of prolactin receptor and prolactin in normal and malignant thyroid: a tissue microarray study. Endocr Pathol 2006;17:377-86.
31. Plaza Menacho I, Koster R, van der Sloot AM, Quax WJ, Osinga J, van der Sluis T, Hollema H, Burzynski GM, Gimm O, Buys CH, Eggen BJ, Hofstra RM. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. Cancer Res 2005;65:1729-37.